Pyxis Oncology (PYXS) Liabilities and Shareholders Equity (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $91.5 million in Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity fell 41.77% year-over-year to $91.5 million in Q4 2025; TTM through Dec 2025 was $456.2 million, a 41.59% decrease from a year earlier, with the FY2025 full-year figure at $91.5 million, down 41.77% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $91.5 million, down from $105.6 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for PYXS reached as high as $280.0 million in Q4 2021 and fell as low as $91.5 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $183.7 million across 5 years, with a median of $184.7 million in 2023.
• Across the five-year window, Liabilities and Shareholders Equity surged 2658.56% in 2021 and sank 45.93% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $280.0 million in 2021, then decreased by 24.51% to $211.4 million in 2022, then fell by 17.81% to $173.7 million in 2023, then fell by 9.52% to $157.2 million in 2024, then tumbled by 41.77% to $91.5 million in 2025.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $91.5 million in Q4 2025, $105.6 million in Q3 2025, and $123.2 million in Q2 2025.